Autoimmune Disease Treatment Market Size & Share, by Drug (NSAIDs, Anti-Inflammatory, Interferons, Antihyperglycemics); Disease (Rheumatoid Arthritis, Type 1 Diabetes, Multiple Sclerosis, Psoriasis, Lupus, Inflammatory Bowel Disease); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 2362
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Autoimmune Disease Treatment Market size was over USD 7.13 billion in 2024 and is poised to exceed USD 18.26 billion by 2037, witnessing over 7.5% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of autoimmune disease treatment is evaluated at USD 7.58 billion.


Autoimmune Disease Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Improvement In Government Regulations Regarding Drug Approvals To Drive Autoimmune disease treatment Market
    Recently, a few autoimmune disease treatment have received approvals for sale in the market. For instance, RITUXIN is a drug manufactured by Genentech, which received FDA approval for the treatment of rheumatoid arthritis. Various other drugs are still in the clinical trials stage and observing positive results. This is anticipated to become a major factor for the growth of autoimmune disease treatment market over the forecast period. The increasing research and development in the area of autoimmune disease is predicted to lead to more drug approvals in future.
  • Rising Awareness about Autoimmune Disease to Boost the Market Growth
    Growing prevalence of various autoimmune diseases poses a high risk to individuals, especially the elderly population. Rheumatoid arthritis is an autoimmune disease in which the immune system attacks the joints in the body, commonly those in hands, knees and wrists. This causes inflammation in the affected body part and inhibits normal body functioning. According to Centers for Disease Prevention and Control, around 22.7% or 54.4 million adults in America had doctor-diagnosed arthritis as per the National Health Interview Survey 2013-3015, with a higher prevalence in women (23.5%) than in men (18.1%). The growing demand for reducing the effects of this disorder is anticipated to result in growth of the market.

Challenges

  • High Cost Of Treatment To Restrict The Market Growth
    The high cost of treatment for autoimmune disease coupled with availability of alternate treatment methods in the market are some major factors estimated to hinder the growth of autoimmune disease market over the forecast period.

Autoimmune Disease Treatment Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

7.50%

Base Year Market Size (2024)

USD 7.13 billion

Forecast Year Market Size (2037)

USD 18.26 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Autoimmune Disease Treatment Segmentation

The market is segmented by drug, by disease, by distribution channel and by region. Based on disease, the market is segmented into rheumatoid arthritis, type 1 diabetes, multiple sclerosis, psoriasis, lupus, inflammatory bowel disease and others. The high prevalence of rheumatoid arthritis globally can be attributed to the significantly high share of this segment in the market over the next few years. On the basis of drugs, the market is segmented into NSAIDs, anti-inflammatory, interferons, antihyperglycemics and others, out of which, the anti-inflammatory segment is anticipated to hold the largest share in the autoimmune disease treatment market on account of their application in large number of indications such as rheumatoid arthritis, juvenile idiopathic arthritis, gout, psoriasis, ankylosing spondylitis and others. XELJANZ, a drug for oral use manufactured by Pfizer and approved by the U.S. FDA in 2012, aimed at treating both rheumatoid arthritis and psoriatic arthritis among adult patients having an inadequate response to methotrexate. 

Our in-depth analysis of the global market includes the following segments

By Drug

  • NSAIDs
  • Anti-Inflammatory
  • Interferons
  • Antihyperglycemics 
  • Others

By Disease

  • Rheumatoid Arthritis
  • Type 1 Diabetes
  • Multiple Sclerosis
  • Psoriasis
  • Lupus
  • Inflammatory Bowel Disease
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Autoimmune Disease Treatment Industry - Regional Synopsis

On the basis of regional analysis, the autoimmune disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is likely to dominate majority revenue share by 2037, as a result of rising research and development activities focused on finding a treatment for autoimmune disease. Moreover, the increasing investment in the healthcare sector in the region is another factor estimated to result in the market growth in the coming years. The highest growth rate of autoimmune disease treatment market is anticipated to be observed in the Asia Pacific region on account of significantly improving healthcare infrastructure and development of better treatment facilities. The growing awareness among people about autoimmune disease further raises the demand for the drugs in the region which is another growth driving factor for the autoimmune disease treatment market over the forecast period.

Research Nester
Get more information on this report: Request Free Sample PDF

Companies Dominating the Autoimmune Disease Treatment Landscape

    • Abbott Laboratories
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer
    • AbbVie
    • Eli Lilly
    • Bristol-Myers Squibb
    • AstraZeneca plc
    • GlaxoSmithKline
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Amgen

Author Credits:  Radhika Pawar


  • Report ID: 2362
  • Published Date: Dec 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of autoimmune disease treatment is evaluated at USD 7.58 billion.

Autoimmune Disease Treatment Market size was over USD 7.13 billion in 2024 and is poised to exceed USD 18.26 billion by 2037, witnessing over 7.5% CAGR during the forecast period i.e., between 2025-2037.

North America industry is likely to dominate majority revenue share by 2037, as a result of rising research and development activities focused on finding a treatment for autoimmune disease.

The major players in the market are Abbott Laboratories, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, AstraZeneca plc, GlaxoSmithKline, F. Hoffmann-La Roche Ltd., Biogen and Amgen.
Autoimmune Disease Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample